- Home
- Publications
- Publication Search
- Publication Details
Title
Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 13, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2022-07-13
DOI
10.3389/fimmu.2022.940674
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
- (2021) Jason J Luke et al. Journal for ImmunoTherapy of Cancer
- Designed proteins assemble antibodies into modular nanocages
- (2021) Robby Divine et al. SCIENCE
- Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer
- (2021) Christopher S. Garris et al. Science Translational Medicine
- Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy
- (2021) Marie Siwicki et al. Science Immunology
- Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity
- (2020) Xiaojie Yu et al. CANCER CELL
- CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
- (2020) Caroline Bonnans et al. Journal for ImmunoTherapy of Cancer
- cDC1 prime and are licensed by CD4+ T cells to induce anti-tumour immunity
- (2020) Stephen T. Ferris et al. NATURE
- CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study
- (2020) Mark H O'Hara et al. LANCET ONCOLOGY
- First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies
- (2019) Sandra M. M. Irenaeus et al. INTERNATIONAL JOURNAL OF CANCER
- A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer
- (2019) Joanie Del Bano et al. Frontiers in Immunology
- CD40 Agonist Antibodies in Cancer Immunotherapy
- (2019) Robert H. Vonderheide Annual Review of Medicine
- A BISPECIFIC MOLECULE TARGETING CD40 AND TUMOR ANTIGEN MESOTHELIN ENHANCES TUMOR-SPECIFIC IMMUNITY
- (2019) Shiming Ye et al. Cancer Immunology Research
- Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility
- (2019) Xiaobo Liu et al. Nature Communications
- The Immune Revolution: A Case for Priming, Not Checkpoint
- (2018) Robert H. Vonderheide CANCER CELL
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
- (2018) David A. Knorr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
- (2017) Andrew W Hahn et al. Immunotherapy
- A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.
- (2017) P. W. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement
- (2016) Rony Dahan et al. CANCER CELL
- Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model
- (2016) Nadia M. Luheshi et al. Oncotarget
- CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
- (2016) Katelyn T. Byrne et al. Cell Reports
- Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies
- (2015) Ann L. White et al. CANCER CELL
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study
- (2015) P. Johnson et al. CLINICAL CANCER RESEARCH
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- A Short History of the B-Cell-Associated Surface Molecule CD40
- (2014) Edward A. Clark Frontiers in Immunology
- CD40 immunotherapy for pancreatic cancer
- (2013) Robert H. Vonderheide et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Agonistic CD40 Antibodies and Cancer Therapy
- (2013) R. H. Vonderheide et al. CLINICAL CANCER RESEARCH
- Antitumor activities of agonistic anti-TNFR antibodies require differential Fc RIIB coengagement in vivo
- (2013) F. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial
- (2013) F. Chowdhury et al. Cancer Immunology Research
- Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer
- (2013) L. C. Sandin et al. Cancer Immunology Research
- Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors
- (2013) Robert H. Vonderheide et al. OncoImmunology
- Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors
- (2011) Jens Rüter et al. CANCER BIOLOGY & THERAPY
- Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody
- (2011) M. F. Fransen et al. CLINICAL CANCER RESEARCH
- Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody
- (2011) A. L. White et al. JOURNAL OF IMMUNOLOGY
- Inhibitory Fc Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies
- (2011) F. Li et al. SCIENCE
- A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia
- (2010) Richard R. Furman et al. LEUKEMIA & LYMPHOMA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started